Annexin V, Human Recombinant: Precision Apoptosis Detection Reagent

Executive Summary: Annexin V, human recombinant is a calcium-dependent phosphatidylserine (PS) binding protein and established early apoptosis marker (Burger et al., 1993). During programmed cell death, Annexin V detects PS externalization on the cell surface, supporting sensitive and specific apoptosis assays. APExBIO’s Annexin V (SKU K2064) is supplied as a 1 mg/mL liquid formulation in PBS (pH 7.4) and can be conjugated to diverse detection tags. The reagent is validated for flow cytometry and fluorescence microscopy, and is intended for research use only. Proper storage at -20°C ensures long-term stability and reproducibility (product page).

Biological Rationale

Annexin V is a member of the annexin superfamily, comprising over ten proteins that bind acidic phospholipids in a Ca2+-dependent manner [Burger et al., 1993]. In healthy cells, phosphatidylserine (PS) is confined to the cytoplasmic leaflet of the plasma membrane. Upon initiation of apoptosis, PS is translocated to the outer leaflet, where it becomes accessible to Annexin V (Annexin V in Apoptosis Assays). This translocation is an evolutionarily conserved hallmark of early apoptosis. Because this event precedes cell membrane rupture, Annexin V binding distinguishes apoptotic from necrotic or viable cells. This specificity underpins its universal adoption as a cell death biomarker in cancer, neurodegenerative, and immunological research (Annexin V: Mechanistic Insight).

Mechanism of Action of Annexin V, human recombinant

Annexin V binds to PS in the presence of Ca2+ ions, with high affinity (Kd ~1 nM) (Burger et al., 1993). The protein consists of four homologous domains, each forming five α-helices. Calcium binding sites are located on the convex face of the molecule, mediating interaction with the negatively charged headgroups of PS. When PS is exposed on the cell surface, Annexin V forms a two-dimensional lattice that stabilizes binding. This process is reversible and strictly calcium-dependent: removal of Ca2+ (e.g., by EDTA chelation) abrogates binding. Recombinant forms, such as APExBIO’s Annexin V (K2064), retain this biochemistry and are suitable for conjugation to fluorophores (FITC, PE) or other tags for detection.

• Annexin V competitively inhibits phospholipase A1 activity and blocks blood coagulation by competing for PS binding sites (Burger et al., 1993).
• In vitro, Annexin V can form voltage-gated ion channels, but its primary use in apoptosis assays leverages its PS-binding property (Burger et al., 1993).

Evidence & Benchmarks

• Annexin V binds PS on apoptotic cells with nanomolar affinity under physiological calcium concentrations (1–2 mM Ca2+) (Burger et al., 1993).
• Annexin V staining is detectable in early apoptosis, prior to membrane permeabilization or DNA fragmentation (Burger et al., 1993).
• Recombinant Annexin V can be purified to homogeneity using calcium-mediated liposome binding and ion-exchange chromatography—yielding a single peak by HPLC (Burger et al., 1993).
• APExBIO’s Annexin V, human recombinant (SKU K2064) is validated for flow cytometry and microscopy, with typical working concentrations of 1–5 µg/mL in apoptosis assays (product page).
• Annexin V binding is strictly calcium-dependent; chelation by EDTA abolishes signal, confirming assay specificity (Burger et al., 1993).

Applications, Limits & Misconceptions

Annexin V, human recombinant is widely used in:

• Apoptosis detection in cancer, neurodegenerative, and immunology research.
• Flow cytometry, fluorescence microscopy, and plate-based apoptosis assays.
• Competition binding experiments to validate PS exposure or block enzymatic activity.
• Development of multiplexed assays with labeled Annexin V conjugates (e.g., FITC, PE).

This article extends prior coverage (Annexin V: Mechanistic Insight) by detailing the molecular mechanism and workflow parameters for the unlabeled, human recombinant format, whereas previous articles focused on translational utility and workflow scenarios with tagged reagents. For practical troubleshooting and case-driven guidance, see Annexin V (SKU K2064): Reliable Apoptosis Detection in Cell Assays, which provides scenario-based optimization tips not covered here.

Common Pitfalls or Misconceptions

• Annexin V does not detect necrosis specifically: PS exposure during necrosis or late-stage apoptosis can yield positive staining; proper counterstaining (e.g., with propidium iodide) is required for discrimination.
• Calcium-dependence is absolute: Annexin V binding fails without physiological Ca2+ (1–2 mM); EDTA or low-Ca2+ buffers result in false negatives.
• Not suitable for in vivo imaging without modification: Unlabeled Annexin V cannot be tracked in animal models unless conjugated to a detectable moiety.
• Not a diagnostic or therapeutic agent: APExBIO’s Annexin V is for research use only; clinical or diagnostic applications are not validated.
• False positives in cells with membrane damage: Mechanical or chemical injury can also externalize PS, leading to non-apoptotic Annexin V staining.

Workflow Integration & Parameters

APExBIO’s Annexin V, human recombinant (SKU K2064) is supplied at 1 mg/mL in PBS (pH 7.4). Store at -20°C to maintain activity. Lyophilized formats can be reconstituted in water or PBS to 1–5 mg/mL. Before use, briefly centrifuge the vial to ensure solution homogeneity. For flow cytometry or microscopy:

• Dilute Annexin V to 1–5 µg/mL in binding buffer with 1–2 mM Ca2+.
• Incubate cells for 10–15 min at room temperature, protected from light if using tagged conjugates.
• Wash cells gently to remove unbound protein.
• Combine with vital dyes (e.g., propidium iodide) to distinguish apoptosis from necrosis.

For competition or inhibitor studies, unlabeled K2064 can be titrated against labeled conjugates to quantify PS accessibility or block enzymatic reactions. For advanced translational workflows, see Annexin V: Mechanistic Precision and Strategic Value in Translational Research, which discusses multiparametric cell death models and regulatory considerations.

Conclusion & Outlook

Annexin V, human recombinant (APExBIO SKU K2064) is a validated, Ca2+-dependent apoptosis detection reagent with robust performance across cell death research. Its molecular mechanism, optimized formulation, and compatibility with multiple detection modalities ensure reproducibility for cancer, neurodegenerative, and immune research. Proper buffer conditions and workflow integration are critical for assay specificity. As apoptosis research advances, recombinant Annexin V will remain a linchpin for early cell death detection and mechanistic studies.

For technical details, protocols, or to order, visit the Annexin V, human recombinant product page.